title: Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin.
abstract: Rapidly growing mycobacteria (RGM) and Nocardiae can cause severe or refractory infections in cats and dogs. Prolonged antibacterial therapy is required to cure these infections. As fluoroquinolones have been used in combination therapy for treating RGM infections, isolates from the Mycobacterium smegmatis cluster (n=64), Mycobacterium fortuitum cluster (n=17), and M. mageritense cluster (n=2), collected from feline and canine patients, underwent susceptibility testing to pradofloxacin. The MIC(50), MIC(90) and tentative epidemiological cut-off (ECOFF) values as determined by microbroth dilution susceptibility testing that inhibited growth of the M. smegmatis and M. fortuitum clusters were 0.063, 0.125 and ≤ 0.25; and 0.125, 0.250 and ≤ 1.0 μg/mL, respectively. E-Test results showed similar trends but MICs were lower than those for microbroth dilution. In summary, pradofloxacin demonstrated effective in vitro activity against RGM isolates. Additionally, veterinary isolates of Nocardia nova (n=18), Nocardia farcinica (n=3) and Nocardia cyriacigeorgica (n=1) underwent microbroth dilution testing to ciprofloxacin, enrofloxacin and pradofloxacin. The MIC(50) and MIC(90) of pradofloxacin, ciprofloxacin and enrofloxacin that inhibited growth of Nocardia nova isolates were 2 (4), 8 (16), 16 (32) μg/mL, respectively. The tentative ECOFF values for pradofloxacin and ciprofloxacin were 32 μg/mL and for enrofloxacin 64 μg/mL. The MIC or MIC range for the three N. farcinica isolates of pradofloxacin, ciprofloxacin and enrofloxacin were 0.25-0.5, 2 and 2 μg/mL and for the single N. cyriacigeorgica isolate were 1, 4 and 4 μg/mL, respectively. On the basis on these results, fluoroquinolones appear to have limited therapeutic potential for most Nocardia infections.
authors: Faculty of Veterinary Science, McMaster building, B14, The University of Sydney, NSW 2006, Australia. merran.govendir@sydney.edu.au
authors: M
authors: M
authors: Govendir
authors: J M
authors: JM
authors: Norris
authors: T
authors: T
authors: Hansen
authors: D I
authors: DI
authors: Wigney
authors: G
authors: G
authors: Muscatello
authors: D J
authors: DJ
authors: Trott
authors: R
authors: R
authors: Malik
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002371:Cat Diseases / Q000382:microbiology*; D002415:Cats; D002939:Ciprofloxacin / Q000494:pharmacology; D004283:Dog Diseases / Q000382:microbiology*; D004285:Dogs; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D009161:Mycobacterium / Q000187:drug effects* / Q000254:growth & development; D009164:Mycobacterium Infections / Q000382:microbiology / Q000662:veterinary*; D009615:Nocardia / Q000187:drug effects* / Q000254:growth & development; D009617:Nocardia Infections / Q000382:microbiology / Q000662:veterinary*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin; C507250:pradofloxacin